ARTICLE | Clinical News
CTLA4-Ig: Phase I interim data
May 3, 2004 7:00 AM UTC
In a U.S., open-label, dose-escalating Phase I study in patients with relapsing-remitting MS, a single dose of CTLA4-Ig at 2mg/kg or 10mg/kg was safe. Patients received a single dose of CTLA4-Ig at 2,...